Acorda gains on MS data

Acorda (NASDAQ:ACOR) gained $6.74 (31%) to $28.30 on Monday after reporting that Fampridine-SR met the primary endpoint in the Phase III MS-F204 trial to treat multiple sclerosis. The primary endpoint...